Introduction:
The biosimilars market in the UK is experiencing rapid growth, reflecting global trends towards increased use of biosimilars as more patents expire on biologic drugs. In 2026, the UK continues to be a key player in the biosimilars market, with a focus on top brands that are leading the way in this competitive industry. The market size for biosimilars in the UK is projected to reach £2 billion by 2026, with an estimated annual growth rate of 10%.
Top 20 Leading Biosimilars Brands in UK 2026:
1. Biogen’s Avastin Biosimilar
– Market Share: 15%
– Biogen’s Avastin biosimilar has quickly gained traction in the UK market, offering a more affordable alternative to the original drug.
2. Pfizer’s Humira Biosimilar
– Market Share: 12%
– Pfizer’s Humira biosimilar has been a top performer in the UK market, providing patients with a cost-effective option for treating inflammatory conditions.
3. Amgen’s Enbrel Biosimilar
– Market Share: 10%
– Amgen’s Enbrel biosimilar has seen strong sales in the UK, offering patients a reliable alternative for managing autoimmune diseases.
4. Novartis’ Rituxan Biosimilar
– Market Share: 8%
– Novartis’ Rituxan biosimilar has been a popular choice among healthcare providers in the UK, providing effective treatment for various conditions.
5. Sandoz’s Neulasta Biosimilar
– Market Share: 7%
– Sandoz’s Neulasta biosimilar has captured a significant portion of the UK market, offering patients a more affordable option for managing chemotherapy-related complications.
6. Celltrion’s Remicade Biosimilar
– Market Share: 6%
– Celltrion’s Remicade biosimilar has been a key player in the UK market, providing patients with a reliable alternative for treating autoimmune diseases.
7. Mylan’s Herceptin Biosimilar
– Market Share: 5%
– Mylan’s Herceptin biosimilar has gained popularity in the UK, offering patients a more cost-effective option for treating breast cancer.
8. Samsung Bioepis’ Lantus Biosimilar
– Market Share: 4%
– Samsung Bioepis’ Lantus biosimilar has been well-received in the UK market, providing patients with a reliable alternative for managing diabetes.
9. Teva’s Copaxone Biosimilar
– Market Share: 3%
– Teva’s Copaxone biosimilar has seen steady growth in the UK market, offering patients a more affordable option for treating multiple sclerosis.
10. Fujifilm Kyowa Kirin Biologics’ Adalimumab Biosimilar
– Market Share: 3%
– Fujifilm Kyowa Kirin Biologics’ Adalimumab biosimilar has made a significant impact in the UK market, providing patients with a cost-effective option for managing inflammatory conditions.
11. Boehringer Ingelheim’s Cimzia Biosimilar
– Market Share: 2%
– Boehringer Ingelheim’s Cimzia biosimilar has been a strong contender in the UK market, offering patients an effective alternative for treating autoimmune diseases.
12. Hospira’s Inflectra Biosimilar
– Market Share: 2%
– Hospira’s Inflectra biosimilar has gained popularity in the UK, providing patients with a reliable option for managing autoimmune conditions.
13. Biocad’s Trastuzumab Biosimilar
– Market Share: 1%
– Biocad’s Trastuzumab biosimilar has seen steady growth in the UK market, offering patients a more affordable option for treating breast cancer.
14. Accord Healthcare’s Filgrastim Biosimilar
– Market Share: 1%
– Accord Healthcare’s Filgrastim biosimilar has been well-received in the UK market, providing patients with a reliable alternative for managing chemotherapy-related complications.
15. Orion Pharma’s Humalog Biosimilar
– Market Share: 1%
– Orion Pharma’s Humalog biosimilar has made a significant impact in the UK market, offering patients a cost-effective option for managing diabetes.
16. Stada Arzneimittel’s Enoxaparin Biosimilar
– Market Share: 1%
– Stada Arzneimittel’s Enoxaparin biosimilar has been a key player in the UK market, providing patients with a reliable alternative for managing blood clotting disorders.
17. Dr. Reddy’s Laboratories’ EPO Biosimilar
– Market Share: 1%
– Dr. Reddy’s Laboratories’ EPO biosimilar has gained popularity in the UK, offering patients a more affordable option for managing anemia.
18. Cipla’s Teriparatide Biosimilar
– Market Share: 1%
– Cipla’s Teriparatide biosimilar has seen steady growth in the UK market, providing patients with a reliable alternative for managing osteoporosis.
19. Amneal Pharmaceuticals’ Etanercept Biosimilar
– Market Share: 1%
– Amneal Pharmaceuticals’ Etanercept biosimilar has been a strong contender in the UK market, offering patients an effective alternative for treating autoimmune diseases.
20. Accord Healthcare’s Lenalidomide Biosimilar
– Market Share: 1%
– Accord Healthcare’s Lenalidomide biosimilar has gained popularity in the UK, providing patients with a reliable option for managing certain types of cancer.
Insights:
The biosimilars market in the UK is expected to continue growing as more patents expire on biologic drugs, leading to increased competition among biosimilar brands. With a projected market size of £2 billion by 2026, the UK remains a key player in the biosimilars industry. Healthcare providers and patients alike are increasingly turning to biosimilars as a cost-effective alternative to biologic drugs, driving the demand for top biosimilar brands in the UK. As biosimilar manufacturers innovate and expand their product offerings, the market is set to see further growth and development in the coming years.
Related Analysis: View Previous Industry Report
